Pfizer is recalling approximately 4.2 million units of Nurtec ODT (rimegepant) 75 mg orally disintegrating tablets sold in 8-unit dose blister packs. The packaging of these prescription drugs is not child-resistant as required by the Poison Prevention Packaging Act, posing a poisoning hazard if a child swallows the tablets. These medications were sold at pharmacies nationwide from December 2021 through March 2023. No injuries have been reported, and Pfizer is providing free child-resistant pouches so patients can continue to use their medicine safely.
The current blister card packaging is not child-resistant, which means young children can easily access and swallow the medication. If ingested by a child, these tablets pose a significant risk of poisoning. No incidents or injuries have been reported to date.
Consumers should immediately secure the recalled product out of the sight and reach of children and contact Pfizer for a free child resistant pouch to store the product. Once the product is secured, consumers can continue to use it as directed.
Recall includes all expiration dates through 6/2026. Dosage strength and expiration date are printed or stamped on the blister card.
Recalled Nurtec® ODT (rimegepant) orally disintegrating tablets
Recalled Nurtec® ODT (rimegepant) orally disintegrating tablets (blister packaging)
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: CPSC Notice · Raw API Response